FDA Comes Under Fire From Sen. Clinton Over Plan B Decision
This article was originally published in The Pink Sheet Daily
The New York Democrat seeks a Senate Health Committee oversight hearing and General Accounting Office investigation as part of full review of FDA’s rejection of OTC status for the emergency contraceptive.
You may also be interested in...
Group led by Rep. Waxman is requesting that GAO examine communications between the White House and HHS regarding FDA's decision not to approve the Plan B emergency contraceptive switch application.
Dunn’s participation at the panel meeting ended speculation that he left the US FDA.
Or can industry thread the donut hole and prevent government price negotiations from becoming a part of the legislative tsunami?